This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Author contributions: Sakurai K performed the research and wrote the paper; all of the authors designed the experiments and contributed to data collection. Sakurai K and Suda H contributed to the analysis; all of the authors read and approval the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Hattori Clinic’s Ethical Committee.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: Authors declare no conflict of interest related to this manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Received: September 14, 2016 Peer-review started: September 15, 2016 First decision: October 10, 2016 Revised: October 26, 2016 Accepted: November 15, 2016 Article in press: November 16, 2016 Published online: January 28, 2017 Processing time: 126 Days and 15.2 Hours
Core Tip
Core tip: Because the Helicobacter pylori (H. pylori) eradication rate of conventional proton pump inhibitor (PPI)-based treatment has decreased because clarithromycin-resistant strains have appeared in recent years, a new treatment strategy is required. Vonoprazan is a novel potassium -competitive acid blocker that has strong, long-lasting effects, but few studies have investigated its efficacy against H. pylori. We compared vonoprazan-based therapy and PPI-based therapy as first-line and second-line treatments. Vonoprazan-based therapy was superior to PPI-based therapy, particularly for smokers, but adverse events (AEs) due to vonoprazan occurred more frequently. Vonoprazan-based therapy is a potentially efficacious treatment, but it should be used with caution due to possible AEs.
